At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 21 enrolled
Drug / intervention
Apremilast +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Three-period, Fixed-sequence Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Apremilast, Rifampin Oral Capsules, and 1 other intervention for Healthy Subjects. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate how the pharmacokinetics of apremilast may be affected by a single intravenous dose of rifampin and multiple oral doses of rifampin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Subjects
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedMar 2012
Primary CompletionApr 2012
TodayJul 2026
First PostedMar 23, 2012
Enrollment StartFeb 1, 2012
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.3 years ago
Interventions
Apremilastdrug
Tablets for oral administration
Rifampin Oral Capsulesdrug
Capsules for oral administration
Rifampin IV Solutiondrug
Intravenous (IV) solution